Reference
Wagener-Ryczek S, et al. Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors. BMC Cancer 20: No. 1, 12 May 2020. Available from: URL: http://doi.org/10.1186/s12885-020-06920-3
Rights and permissions
About this article
Cite this article
Afatinib/erlotinib/gefitinib. Reactions Weekly 1847, 27 (2021). https://doi.org/10.1007/s40278-021-92584-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-92584-1